$PGEN Follow-Up — Did anyone here actually ride this thesis with me?
Hey Traders,
I posted my original thesis on $PGEN when this was still mostly a story about potential.
Back then the big question was simple:
Can PAPZIMEOS actually become a real commercial biotech success?
Well… now we have the first real answer.
Q1 just dropped, and honestly, this was a much stronger report than what many expected.
Key takeaways:
• PAPZIMEOS delivered $21.6M in net product revenue in its first real commercial quarter
• Approximately 400 patients enrolled in the patient hub
• 25% of enrollment now coming from community settings (important because this shows adoption beyond major academic centers)
• Coverage now reaches ~297M insured lives (>90% of insured US population)
• Permanent reimbursement J-code now active
• Management says current cash + expected PAPZIMEOS revenue should fund operations to cash flow breakeven by end of 2026
That last part matters.
Because one of the biggest bear arguments was always:
“Great science… but inevitable dilution.”
That thesis just got weaker.
The commercial story now looks much more real.
This is what changes biotech valuations:
Not press releases.
Not hype.
Not pipeline dreams.
Commercial execution.
What I find interesting:
The market was treating PGEN like another speculative biotech…
but this may be transitioning into a legitimate commercial growth story.
Now the next question becomes:
Can Q2 confirm acceleration?
Because if PAPZIMEOS continues ramping, valuation assumptions may need to be repriced.
I’ve been following this story closely since before approval, and I’m curious:
Did anyone here actually take the original thesis with me?
Would love to hear how others are positioning after this earnings report.
Not financial advice. Do your own DD.